Companies › Haihe Biopharma
3 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology, Other; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CYH33 PIK3CA inhibitor | PIK3CA | Phase 2 | Ovarian Cancer; PIK3CA-Related Overgrowth Spectrum (PROS) | Dec 2029 |
| HH2853 | – | Phase 1 | Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL); FL Lymphoma | Jul 2027 |
| Glumetinib MEK inhibitor | MAP2K1 | Phase 1 | C-Met Exon 14 Mutation | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04270591 | Glumetinib | Phase 1 | C-Met Exon 14 Mutation | Other | Oct 2023 |
| NCT05043922 | CYH33 | Phase 2 | Ovarian Cancer | Oncology | Jul 2024 |
| NCT06909877 | HH2853 | Phase 1 | Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL) | Oncology | Jul 2027 |
| NCT04390737 | HH2853 | Phase 1 | FL Lymphoma | Oncology | Dec 2027 |
| NCT06975618 | CYH33 | Phase 1 | PIK3CA-Related Overgrowth Spectrum (PROS) | Other | Dec 2029 |
Relay Therapeutics Ranok Therapeutics (Hangzhou) Shanghai Kechow Pharma Monte Rosa Therapeutics Beijing Tide Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.